Phaseline

Companies › Vensica Therapeutics

Vensica Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Genitourinary; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NT 201 200U
Botulinum toxin type A
SNAREPhase 2Overactive Bladder (OAB)Sep 2027
NT 201 300U
Botulinum toxin type A
SNAREPhase 2Overactive Bladder (OAB)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07553065NT 201 200UPhase 2Overactive Bladder (OAB)GenitourinarySep 2027
NCT07553065NT 201 300UPhase 2Overactive Bladder (OAB)GenitourinarySep 2027

Targets

SNARE (2)

Companies with the same targets

Eirion Therapeutics

Companies built like this

YolTech Therapeutics Cisen Pharmaceutical Levee Medical Urotronic Prokidney

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.